A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients greater than or equal to 60 Years With Previously Untreated Chronic Lymphocytic Leukemia.

Trial Profile

A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients greater than or equal to 60 Years With Previously Untreated Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 May 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Interim results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top